1.Development and Feasibility Evaluation of Smart Cancer Care 2.0 Based on Patient-Reported Outcomes for Post-Discharge Management of Patients with Cancer
Jin Ah KWON ; Songsoo YANG ; Su-Jin KOH ; Young Ju NOH ; Dong Yoon KANG ; Sol Bin YANG ; Eun Ji KWON ; Jeong-Wook SEO ; Jin sung KIM ; Minsu OCK
Cancer Research and Treatment 2024;56(4):1040-1049
Purpose:
A “Smart Cancer Care” platform that integrates patient-reported outcomes (PROs) with management has been established in Korea. This study focused on improving health behaviors and connecting patients to welfare services by introducing and assessing the feasibility of “Smart Cancer Care 2.0,” an enhanced version designed for monitoring complications post-cancer treatment.
Materials and Methods:
Smart Cancer Care 2.0 was developed by conducting a literature review and consulting with expert panels to identify symptoms or variables requiring monitoring and management guidelines based on the treatment type. Qualitative and quantitative surveys were conducted to assess the feasibility of the app and web system based on the experiences of patients with cancer and healthcare workers.
Results:
A total of 81 symptoms or variables (chemotherapy-, surgery-, radiotherapy-, rehabilitation-, and health management-related) were selected for management in Smart Cancer Care 2.0. PROs for these symptoms were basically categorized into three severity grades: preventive management, self-treatment, and consultation with a healthcare worker or visit to a healthcare institution. The overall mean scores in the feasibility evaluation by patients and healthcare workers were 3.83 and 3.90 points, respectively, indicating high usefulness.
Conclusion
Smart Cancer Care 2.0 leverages the existing information and communication technologies–based platform, Smart Cancer Care, and further includes health behaviors and welfare services. Smart Cancer Care 2.0 may play a crucial role in establishing a comprehensive post-discharge management system for patients with cancer as it provides suitable interventions based on patients’ responses and allows the regularly collected PROs to be easily viewed for streamlined care.
2.Uptake of Family-Specific Mutation Genetic Testing Among Relatives of Patients with Ovarian Cancer with BRCA1 or BRCA2 Mutation
Go Woon JEONG ; Wonkyo SHIN ; Dong Ock LEE ; Sang-Soo SEO ; Sokbom KANG ; Sang-Yoon PARK ; Myong Cheol LIM
Cancer Research and Treatment 2021;53(1):207-211
Purpose:
The BRCA1 or BRCA2 gene is transmitted in an autosomal dominant fashion, and genetic testing of first-degree relatives of patients with family-specific mutation (FSM) is recommended. This study examined factors affecting the uptake of FSM testing among relatives of patients with peritoneal, ovarian, or fallopian tube (POFT) cancer with confirmed BRCA1 or BRCA2 germline mutation.
Materials and Methods:
Data from medical charts of 392 eligible patients and their relatives who had undergone outpatient genetic counseling/testing were retrospectively reviewed. Clinical factors were compared between family members who had and had not undergone genetic counseling/testing.
Results:
The uptake of FSM testing was 30.5% (129/423) among first-degree living relatives and 53.5% (69/129) within the overall family unit. The average time from genetic testing of the proband to the first FSM test within a family was 168 days (range, 23 to 681 days). Having a living father (33.8% vs. 13.3%, p=0.007) and daughter (79.4% vs. 60.3%, p=0.019) increased the uptake of FSM testing. FSM testing was more likely among female than among male relatives of cancer patients (40.9% vs. 17.6%, p < 0.001).
Conclusion
Approximately one-third of first-degree relatives of patients with a POFT cancer with BRCA1 or BRCA2 mutation underwent FSM testing. Having a living father or daughter was a factor affecting the uptake of FSM testing, which was higher among female than among male relatives of the proband. This discrepancy might be due to a misconception that the BRCA gene is associated with women rather than with men.
3.Patient's Factors at Entering Hospice Affecting Length of Survival in a Hospice Center.
Guk Jin LEE ; Hye Shin AHN ; Se Eun GO ; Ji Hyun KIM ; Min Wu SEO ; Seung Hun KANG ; Yeo Ree YANG ; Mi Yeong LEE ; Ku Ock LEE ; Sang Hoon CHUN ; Jong Youl JIN
Cancer Research and Treatment 2015;47(1):1-8
PURPOSE: In order to provide effective hospice care, adequate length of survival (LOS) in hospice is necessary. However the reported average LOS is much shorter. Analysis of LOS in hospice has not been reported from Korea. We evaluated the duration of LOS and the factors associated with LOS at our hospice center. MATERIALS AND METHODS: We retrospectively examined 446 patients who were admitted to our hospice unit between January 2010 and December 2012. We performed univariate and multivariate analysis for analysis of factors associated with LOS. RESULTS: The median LOS was 9.5 days (range, 1 to 186 days). The LOS of 389 patients (86.8%) was< 1 month. At the time of admission to hospice, 112 patients (25.2%) were completely bedridden, 110 patients (24.8%) had mouth care only without intake, and 134 patients (30.1%) had decreased consciousness, from confusion to coma. The median time interval between the day of the last anticancer treatment and the day of hospice admission was 75 days. By analysis of the results of multivariate analysis, decreased intake and laboratory results showing increased total white blood cell (WBC), decreased platelet count, increased serum creatinine, increased aspartate aminotransferase (AST), alanine aminotransferase (ALT), and lactate dehydrogenase (LDH) level were poor prognostic factors for survival in hospice. CONCLUSION: Before hospice admission, careful evaluation of the patient's performance, particularly the oral intake, and total WBC, platelet, creatinine, AST, ALT, and LDH level is essential, because these were strong predictors of shorter LOS. In the future, conduct of prospective controlled studies is warranted in order to confirm the relationship between potential prognostic factors and LOS in hospice.
Alanine Transaminase
;
Aspartate Aminotransferases
;
Blood Platelets
;
Coma
;
Consciousness
;
Creatinine
;
Hospice Care
;
Hospices*
;
Humans
;
Korea
;
L-Lactate Dehydrogenase
;
Leukocytes
;
Mouth
;
Multivariate Analysis
;
Platelet Count
;
Prognosis
;
Retrospective Studies
;
Survival Analysis
4.A Case of Favorable Responses after Gefitinib in a Patient with EGFR Mutated Adenosquamous Lung Carcinoma.
Nam Jun CHO ; Ho Sung LEE ; Si Hyong JANG ; Jae Sung CHOI ; Ju Ock NA ; Ki Hyun SEO ; Yong Hoon KIM ; Hyo Chul KANG ; Dae Yeon KIM
Soonchunhyang Medical Science 2013;19(2):123-127
In patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutations, the epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are used as first treatment option. Because adenosquamous carcinoma (ASC) is a rare histologic subtype, evidences about EGFR-TKIs as first treatment option for advanced ASC are lacking. We report a case of an advanced ASC patient with the EGFR mutation, who showed good responses during 4-month treatment with gefitinib. And we will review about a necessity of EGFR mutation test and efficacy of EGFR-TKIs in ASC patients from the recent studies.
Carcinoma, Adenosquamous
;
Carcinoma, Non-Small-Cell Lung
;
Epidermal Growth Factor
;
Humans
;
Lung*
;
Phosphotransferases
;
Receptor, Epidermal Growth Factor
5.Quantitative PCR for Etiologic Diagnosis of Methicillin-Resistant Staphylococcus aureus Pneumonia in Intensive Care Unit.
Sun Jung KWON ; Taehyeon JEON ; Dongwook SEO ; Moonjoon NA ; Eu Gene CHOI ; Ji Woong SON ; Eun Hyung YOO ; Chang Gyo PARK ; Hoi Young LEE ; Ju Ock KIM ; Sun Young KIM ; Jaeku KANG
Tuberculosis and Respiratory Diseases 2012;72(3):293-301
BACKGROUND: Ventilator-associated pneumonia (VAP) requires prompt and appropriate treatment. Since methicillin-resistant Staphylococcus aureus (MRSA) is a frequent pathogen in VAP, rapid identification of it, is pivotal. Our aim was to evaluate the utility of quantitative polymerase chain reaction (qPCR) as a useful method for etiologic diagnoses of MRSA pneumonia. METHODS: We performed qPCR for mecA, S. aureus-specific femA-SA, and S. epidermidis-specific femA-SE genes from bronchoalveolar lavage or bronchial washing samples obtained from clinically-suspected VAP. Molecular identification of MRSA was based on the presence of the mecA and femA-SA gene, with the absence of the femA-SE gene. To compensate for the experimental and clinical conditions, we spiked an internal control in the course of DNA extraction. We estimated number of colony-forming units per mL (CFU/mL) of MRSA samples through a standard curve of a serially-diluted reference MRSA strain. We compared the threshold cycle (Ct) value with the microbiologic results of MRSA. RESULTS: We obtained the mecA gene standard curve, which showed the detection limit of the mecA gene to be 100 fg, which corresponds to a copy number of 30. We chose cut-off Ct values of 27.94 (equivalent to 1x10(4) CFU/mL) and 21.78 (equivalent to 1x10(5) CFU/mL). The sensitivity and specificity of our assay were 88.9% and 88.9% respectively, when compared with quantitative cultures. CONCLUSION: Our results were valuable for diagnosing and identifying pathogens involved in VAP. We believe our modified qPCR is an appropriate tool for the rapid diagnosis of clinical pathogens regarding patients in the intensive care unit.
Adenosine
;
Bronchoalveolar Lavage
;
Coat Protein Complex I
;
DNA
;
Humans
;
Critical Care
;
Intensive Care Units
;
Limit of Detection
;
Methicillin Resistance
;
Methicillin-Resistant Staphylococcus aureus
;
Pneumonia
;
Pneumonia, Ventilator-Associated
;
Polymerase Chain Reaction
;
Real-Time Polymerase Chain Reaction
;
Sprains and Strains
;
Stem Cells
6.A Survey on Customers' Perceptions of Nutrition Labeling for Processed Food and Restaurant Meal.
Kwang Il KWON ; Sung Won YOON ; So Jin KIM ; Hani KANG ; Hae Na KIM ; Jee Young KIM ; Seo Young KIM ; Killye KIM ; Jun Hyung LEE ; Sun Mi JUNG ; So Won OCK ; Eun Ju LEE ; Jong Wook KIM ; Myung Chul KIM ; Hye Kyung PARK
The Korean Journal of Nutrition 2010;43(2):181-188
Consumer perception of processed food and restaurant food's nutrient labelling was surveyed. The subjects of this survey consisted of 1,507 parents, whose ages were 20-59 years old. The ratio of the respondents that have known nutrition labelling on processed foods was 89.8% and the ratio of whom have checked the nutrition labelling at their point of purchase was 72.3%. The nutrients which were considered important for nutrition labelling were fat (57.1%), calorie (56.3%) and sodium (49.0%). Also nutrient which were able to be recognized at a glance by the subjects were in the order of trans fat (62.1%), cholesterol (26.9%), calorie (23.9%) and sodium (21.0%). If restaurant menu's nutrient labelling be enacted, the answer rate that the menu's nutrition labelling may affect their menu choice is 90.6% of the respondents. Besides of the Fastfoods that are enforcement, restaurants of that customers want the menu to be labeled were 'pizza and chicken restaurants'. Nutrients that customers preferred to be labelled were calorie (62.0%), fat (60.3%) and sodium (50.9%).
Chickens
;
Cholesterol
;
Food Labeling
;
Humans
;
Meals
;
Parents
;
Restaurants
;
Sodium
;
Surveys and Questionnaires
7.Estimation of CyberKnife Respiratory Tracking System Using Moving Phantom.
Jae Hyuk SEO ; Young Nam KANG ; Ji Sun JANG ; Hun Joo SHIN ; Ji Young JUNG ; Byong Ock CHOI ; Ihl Bohng CHOI ; Dong Joon LEE ; Soo Il KWON ; Jong Soo LIM
Korean Journal of Medical Physics 2009;20(4):324-330
In this study, we evaluated accuracy and usefulness of CyberKnife Respiratory Tracking System (SynchronyTM, Accuray, USA) about a moving during stereotactic radiosurgery. For this study, we used moving phantom that can move the target. We also used Respiratory Tracking System called Synchrony of the Cyberknife in order to track the moving target. For treatment planning of the moving target, we obtained an image using 4D-CT. To measure dose distribution and point dose at the moving target, ion chamber (0.62 cc) and gafchromic EBT film were used. We compared dose distribution (80% isodose line of prescription dose) of static target to that of moving target in order to evaluate the accuracy of Respiratory Tracking System. We also measured the point dose at the target. The mean difference of synchronization for TLS (target localization system) and Synchrony were 11.5+/-3.09 mm for desynchronization and 0.14+/-0.08 mm for synchronization. The mean difference between static target plan and moving target plan using 4D CT images was 0.18+/-0.06 mm. And, the accuracy of Respiratory Tracking System was less 1 mm. Estimation of usefulness in Respiratory Tracking System was 17.39+/-0.14 mm for inactivity and 1.37+/-0.11 mm for activity. The mean difference of absolute dose was 0.68+/-0.38% in static target and 1.31+/-0.81% in moving target. As a conclusion, when we treat about the moving target, we consider that it is important to use 4D-CT and the Respiratory Tracking System. In this study, we confirmed the accuracy and usefulness of Respiratory Tracking System in the Cyberknife.
Four-Dimensional Computed Tomography
;
Prescriptions
;
Radiosurgery
;
Track and Field
8.Estimation of Inhomogeneity Correction Factor in Small Field Dosimetry.
Hun Joo SHIN ; Young Nam KANG ; Jisun JANG ; Jae Hyuk SEO ; Ji Young JUNG ; Byung Ock CHOI ; Ihl Bohng CHOI ; Dong Joon LEE ; Soo Il KWON
Korean Journal of Medical Physics 2009;20(4):260-268
In this study, we estimated inhomogeneity correction factor in small field. And, we evaluated accuracy of treatment planning and measurement data which applied inhomogeneity correction factor or not. We developed the Inhomogeneity Correction Phantom (ICP) for insertion of inhomogeneity materials. The inhomogeneity materials were 12 types in each different electron density. This phantom is able to adapt the EBT film and 0.125 cc ion chamber for measurement of dose distribution and point dose. We evaluated comparison of planning and measurement data using ICP. When we applied to inhomogeneity correction factor or not, the average difference was 1.63% and 10.05% in each plan and film measurement data. And, the average difference of dose distribution was 10.09% in each measurement film. And the average difference of point dose was 0.43% and 2.09% in each plan and measurement data. In conclusion, if we did not apply the inhomogeneity correction factor in small field, it shows more great difference in measurement data. The planning system using this study shows good result for correction of inhomogeneity materials. In radiosurgery using small field, we should be correct the inhomogeneity correction factor, more exactly.
Electrons
;
Radiosurgery
9.ERRATUM: Role of high risk-human papilloma virus test in the follow-up of patients who underwent conization of the cervix for cervical intraepithelial neoplasia.
Jeong Yeol PARK ; Jaeman BAE ; Myong Cheol LIM ; So Yi LIM ; Dong Ock LEE ; Sokbom KANG ; Sang Yoon PARK ; Byung Ho NAM ; Sang Soo SEO
Journal of Gynecologic Oncology 2009;20(3):200-200
No abstract available.
10.Role of high risk-human papilloma virus test in the follow-up of patients who underwent conization of the cervix for cervical intraepithelial neoplasia.
Jeong Yeol PARK ; Jaeman BAE ; Myong Cheol LIM ; So Yi LIM ; Dong Ock LEE ; Sokbom KANG ; Sang Yoon PARK ; Byung Ho NAM ; Sang Soo SEO
Journal of Gynecologic Oncology 2009;20(2):86-90
OBJECTIVE: To examine whether the presence of high risk-human papilloma virus (HR-HPV) after conization of the cervix was a risk factor for persistence or recurrence of cervical intraepithelial neoplasia (CIN) and whether HR-HPV test could be a guideline for post-therapy surveillance. METHODS: The study retrospectively analyzed data from 243 patients who underwent LLETZ or CKC of the cervix due to CIN. RESULTS: A positive HR-HPV test result which was performed between 3 and 6 months after procedure was a risk factor for persistent or recurrent cytological (p<0.001, odds ratio [OR]=22.51, 95% confidence interval [CI]=9.74-52.02) and pathological (p<0.001, OR=18.28, 95% CI=5.55-60.20) abnormalities. CONCLUSION: HR-HPV positive patients between 3 and 6 months after procedure should undergo frequent and meticulous post-therapy surveillance, while HR-HPV negative patients do not require such high-level surveillance and could undergo routine surveillance.
Cervical Intraepithelial Neoplasia
;
Cervix Uteri
;
Conization
;
Female
;
Follow-Up Studies
;
Humans
;
Odds Ratio
;
Papilloma
;
Recurrence
;
Retrospective Studies
;
Risk Factors
;
Viruses

Result Analysis
Print
Save
E-mail